Copyright
©The Author(s) 2022.
World J Clin Oncol. May 24, 2022; 13(5): 417-422
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.417
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.417
Baseline characteristics | Patients, % |
Sex | |
Male | 71 |
Female | 29 |
Age, yr | |
< 65 | 36 |
≥ 65 | 64 |
Location of primary tumour | |
Head-uncinate process | 57 |
Body | 21.5 |
Tail | 21.5 |
Previous surgery | |
Yes | 28.5 |
No | 71.5 |
Number of metastatic sites | |
Single site | 36 |
Multiple sites | 64 |
Location of metastatic sites | |
Lymph nodes | 78.5 |
Liver | 57 |
Peritoneum | 42.8 |
Lung | 35.7 |
First-line chemotherapy regimen | |
Gemcitabine-nab-paclitaxel | 92.8 |
Other | 7.2 |
- Citation: Pretta A, Spanu D, Mariani S, Liscia N, Ziranu P, Pusceddu V, Puzzoni M, Massa E, Scartozzi M, Lai E. How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world. World J Clin Oncol 2022; 13(5): 417-422
- URL: https://www.wjgnet.com/2218-4333/full/v13/i5/417.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i5.417